JAMA Neurol:tau蛋白和Aβ积累与帕金森患者认知

2017-12-15 zhangfan MedSci原创

研究发现,认知正常及中度障碍的帕金森患者与健康志愿者相比,皮质Aβ和tau蛋白积累程度无显著差异。年龄、Aβ以及 tau蛋白不能够预测帕金森患者认知状态。对于帕金森患者以及正常人群,tau蛋白聚集程度与Aβ聚集和年龄相关

多种疾病过程与帕金森病(PD)认知障碍有关,包括路易体病、脑血管病和阿尔茨海默病。近日研究人员对PD认知正常患者(PD-CN)、PD认知中度障碍患者(PD-MCI)以及健康志愿者的tau蛋白聚集程度进行比较,评估Aβ、tau蛋白与无痴呆症状的PD患者认知之间的关系。

研究招募29名PD患者,其中CN15人,MCI 14人。患者接受F18标记AV-1451PET评估tau蛋白聚集,通过C11标记的匹兹堡化合物B磁共振成像评估Aβ,患者同时接受认知测试和神经学评价。49名健康志愿者参与研究。

所有参与者平均年龄71.1岁,女性占60%。6名PD患者(21%)Aβ呈阳性,其中1人存在中度认知障碍;23名PD患者Aβ阴性。在49名对照者中,25人Aβ阴性,24人阳性。全脑tau PET摄取量,Aβ阴性的PD-CN、 PD-MCI以及对照者之间无显著差异。PD-MCI 、PD-CN患者以及Aβ阴性的PD和对照者之间,各脑区反映阿尔茨海默病Braak阶段(1-6)的PET结合能力参数无显著差异。相对于Aβ阴性患者, Aβ阳性患者tau蛋白PET结合能力显著提高,对于Braak3-4级患者,tau蛋白PET结合能力Aβ阳性患者vs阴性患者为1.22 vs 1.14;对于Braak5-6级患者,tau蛋白PET结合能力Aβ阳性患者vs阴性患者为1.20 vs 1.11。

研究发现,认知正常及中度障碍的帕金森患者与健康志愿者相比,皮质Aβ和tau蛋白积累程度无显著差异。年龄、Aβ以及 tau蛋白不能够预测帕金森患者认知状态。对于帕金森患者以及正常人群,tau蛋白聚集程度与Aβ聚集和年龄相关。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000224, encodeId=da6b200022496, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat May 26 07:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270793, encodeId=12ce2e07934f, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Dec 20 06:53:32 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509263, encodeId=38d0150926344, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Sun Dec 17 04:22:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605260, encodeId=86f81605260b8, content=<a href='/topic/show?id=b820309108' target=_blank style='color:#2F92EE;'>#Aβ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3091, encryptionId=b820309108, topicName=Aβ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c19366172, createdName=膀胱癌, createdTime=Sun Dec 17 04:22:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269612, encodeId=2f992696125f, content=研究样本太小了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Dec 15 14:57:00 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2018-05-26 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000224, encodeId=da6b200022496, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat May 26 07:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270793, encodeId=12ce2e07934f, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Dec 20 06:53:32 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509263, encodeId=38d0150926344, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Sun Dec 17 04:22:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605260, encodeId=86f81605260b8, content=<a href='/topic/show?id=b820309108' target=_blank style='color:#2F92EE;'>#Aβ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3091, encryptionId=b820309108, topicName=Aβ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c19366172, createdName=膀胱癌, createdTime=Sun Dec 17 04:22:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269612, encodeId=2f992696125f, content=研究样本太小了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Dec 15 14:57:00 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2017-12-20 1209e435m98(暂无昵称)

    学习了.谢谢分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2000224, encodeId=da6b200022496, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat May 26 07:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270793, encodeId=12ce2e07934f, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Dec 20 06:53:32 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509263, encodeId=38d0150926344, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Sun Dec 17 04:22:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605260, encodeId=86f81605260b8, content=<a href='/topic/show?id=b820309108' target=_blank style='color:#2F92EE;'>#Aβ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3091, encryptionId=b820309108, topicName=Aβ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c19366172, createdName=膀胱癌, createdTime=Sun Dec 17 04:22:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269612, encodeId=2f992696125f, content=研究样本太小了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Dec 15 14:57:00 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2017-12-17 szhvet
  4. [GetPortalCommentsPageByObjectIdResponse(id=2000224, encodeId=da6b200022496, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat May 26 07:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270793, encodeId=12ce2e07934f, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Dec 20 06:53:32 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509263, encodeId=38d0150926344, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Sun Dec 17 04:22:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605260, encodeId=86f81605260b8, content=<a href='/topic/show?id=b820309108' target=_blank style='color:#2F92EE;'>#Aβ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3091, encryptionId=b820309108, topicName=Aβ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c19366172, createdName=膀胱癌, createdTime=Sun Dec 17 04:22:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269612, encodeId=2f992696125f, content=研究样本太小了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Dec 15 14:57:00 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2017-12-17 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=2000224, encodeId=da6b200022496, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat May 26 07:22:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270793, encodeId=12ce2e07934f, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Dec 20 06:53:32 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509263, encodeId=38d0150926344, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Sun Dec 17 04:22:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605260, encodeId=86f81605260b8, content=<a href='/topic/show?id=b820309108' target=_blank style='color:#2F92EE;'>#Aβ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3091, encryptionId=b820309108, topicName=Aβ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee1c19366172, createdName=膀胱癌, createdTime=Sun Dec 17 04:22:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269612, encodeId=2f992696125f, content=研究样本太小了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Dec 15 14:57:00 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2017-12-15 lovetcm

    研究样本太小了

    0

相关资讯

Neurology:研究发现20岁后颞叶新皮层Aβ就开始积累

研究发现,20-60岁人群,Aβ积累量与年龄呈线性相关,Aβ在成年后就开始在内侧额叶和顶叶的积累

景乃禾小组新成果带来攻克阿尔茨海默病的希望

中国科学院上海生命科学研究院生物化学与细胞生物学研究所景乃禾课题组在美国《干细胞报告》上的一项研究成果,让人们看到了攻克阿尔茨海默病的希望。据国际阿尔茨海默病协会发布的《2015年全球阿尔茨海默病报告》,仅2015年1年,就有约1000万阿尔茨海默病新增病例,相当于每分钟约有19人患病。报告预计到2050年,全球阿尔茨海默病患病人数将从当前的4700万增加至1.32亿。遗憾的是,面对持续走高的发病

Neurology:Aβ相关血管炎或为中枢神经系统血管炎不同亚型

该研究的目的是分析脑血管淀粉样蛋白β沉积伴与不伴验性血管浸润的临床表现、治疗效果及临床预后。 研究连续随机纳入1987年至2011年25年终罗切斯特梅奥临床中心78例脑血管Aβ沉积患者。由神经病理学家回顾性分析40例不伴炎症的脑血管Aβ沉积患者(CAA脑淀粉样血管病),28例肉芽肿性血管炎(Aβ相关血管炎或ABRA),10例血管周围CAA相关炎症。该研究同时随机纳入1